Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
Net Change in Cash
Fate Therapeutics Inc
Net Change in Cash Peer Comparison
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fate Therapeutics Inc
NASDAQ:FATE
|
Net Change in Cash
$79.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
6%
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
$11.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$218m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$21.9B
|
CAGR 3-Years
-140%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$126.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fate Therapeutics Inc's Net Change in Cash?
Net Change in Cash
79.2m
USD
Based on the financial report for Mar 31, 2024, Fate Therapeutics Inc's Net Change in Cash amounts to 79.2m USD.
What is Fate Therapeutics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
6%
The average annual Net Change in Cash growth rates for Fate Therapeutics Inc have been 51% over the past three years , -12% over the past five years , and 6% over the past ten years .